Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Four hybridoma clones, TA1, TA2, TA3 and TA4, producing monoclonal antibodies against t-PA were obtained by fusion of mouse myeloma cells (SP2/0 or NS-1) with mouse spleen cells previously immunized with purified t-PA. The antibody titers of the four hybridoma ascites were higher than 1 x 10(5) determined by ELISA. The double immune diffusion test showed that all hybridoma supernatants contained mouse IgG1. These monoclonal antibodies reacted only with t-PA, and rt-PA prepared by genetic engineering, but not with UK. t-PA, activity was inhibited by these monoclonal antibodies completely.
 ...
PMID:Production and characterization of monoclonal antibodies against tissue-type plasminogen activator. 212 98

Six hybridoma cell lines (AP1-AP6) secreting monoclonal antibodies (McAb) against PAI-1 were obtained by fusing the murine myeloma cell line SP2/0 with the spleen cells from Balb/c mouse immunized with recombinant PAI-1 expressed in E. coli. These antibodies were purified by SPA affinity chromatography. All McAbs recognized rPAI-1 and PAI-1 from the human hepatoma cell line HepG2. The titers of ascites were more than 10(6). The antibody-antigen affinity constants (Kaff) for anti-PAI-1 McAb measured by EIA were between 3.45 x 10(7)-1.05 x 10(10) M. AP2 and AP3 McAbs were effective in quenching the activity of PAI-1. Partial quenching of PAI-1 activity was achieved with AP4, AP5 and AP6 McAbs respectively. AP1 McAb had no effect upon PAI-1 activity. Three of the six McAbs (AP1, AP4 and AP5) bound to the PAI-1/t-PA complex, while the others did not. The PAI-1 was purified 51 folds to homogeneity from serum free medium of HepG2 with the recovery rate of 92% by one-step procedure using Sepharose 4B conjugated with anti-PAI-1 McAb (AP1, AP3 and AP4). A sandwich ELISA for the measurement of PAI-1 antigen in human plasma was developed, based on anti-PAI-1 McAb against non-overlapping epitopes. The mean value of plasma PAI-1 for the healthy donors was 24.7 +/- 7.75 ng/ml measured by ELISA.
 ...
PMID:Preparation, characterization and application of monoclonal antibodies against PAI-1. 780 88

The purpose of this review is to provide a biochemical characterization of recombinant prourokinase (r-ProUK [ABT-187]), including a description of its clot-specific fibrinolytic mechanism. In addition, the preclinical data will be briefly reviewed, demonstrating the efficacy of r-ProUK as a potent therapeutic plasminogen activator. r-ProUK was purified to homogeneity from the culture medium of SP2/0 mouse hybridoma cells. The fibrinolytic potency of r-ProUK was characterized by both in vitro clot lysis experiments in human plasma and a canine femoral artery thrombosis model. In the in vitro clot lysis system, with use of clots prepared from fresh frozen human plasma, r-ProUK exhibits a lag phase to the onset of lysis and a concentration-dependent threshold effect due to the presence of the inhibitors alpha 2-antiplasmin and plasminogen activator inhibitor (PAI-1). Effective clot lysis can be achieved without degradation of the fibrinogen in the surrounding plasma. Over a dose range of 50,000-220,000 IU, the canine femoral artery thrombosis model shows a dose-dependent relationship for r-ProUK and effective clot lysis. The lytic activity of r-ProUK is significantly enhanced in this model by the concomitant administration of heparin as an adjunctive agent for thrombolytic treatment. Fibrinogen, plasminogen, and alpha 2-antiplasmin levels in the systemic circulation were unaltered during the 30-minute infusion period and a 4-hour observation period, in which 85% lysis was achieved with r-ProUK (100,000 IU) and heparin. Moreover, restoration of blood flow in the previously fully occluded femoral artery was achieved within minutes of the start of the r-ProUK infusion. The experimental findings presented here are consistent with the clot-specific fibrinolytic mechanism of r-ProUK. Effective clot lysis can be achieved without alteration of the systemic coagulation and fibrinolytic parameters.
 ...
PMID:Fibrinolytic mechanism, biochemistry, and preclinical pharmacology of recombinant prourokinase. 877 Aug 36

To increase thrombolytic specificity of urokinase (uPA), we engineered a recombinant chimeric plasminogen activator SZ51Hu-scuPA, which consists of a humanized monoclonal antibody (SZ-51Hu) specifically against P-selectin on activated human platelet and a single-chain urokinase (scuPA). The cDNA, encoding scuPA amino acids 1-411, was inserted in 5' end to 3' end orientation immediately after the CH3 of SZ-51Hu heavy-chain sequence in the expression vector alphaLys30. The resulting construct alphaLys30-SZ51VH/Hu-scuPA was used to transfect into SP2/0 murine myeloma cell line, which was pretransfected with SZ51Hu light chain. The fusion protein SZ51Hu-scuPA was expressed at 5 mg/L in the supernatant of cell culture. The fusion protein purified by affinity chromatography had a molecular weight of 160 kDa with fibrinolytic activity of 39,000 IU/mg and its affinity to activated human platelet was 67% of the parent murine mAb SZ-51. The thrombolytic property of the fusion protein was first characterized in an in vitro system, which consists of a 125I-fibrin-labeled human plasma clot containing different concentrations of human platelets suspended in citrated human plasma. Fifty percent lysis was reached with SZ51Hu-scuPA in 1 hour at a concentration of 20 IU/mL or in 2 hours at a concentration of 10 IU/ mL, which was much faster than uPA at the same concentration. The maximal lysis of the clots by SZ51Hu-scuPA was 4.1 to 8.4 times more potent than that by uPA. The fusion protein was further characterized in the hamster pulmonary embolism model with clots prepared from fresh platelet-rich human plasma containing 125I-labeled fibrinogen. The thrombolytic activity of SZ51-scuPA was 3.9 times more potent than that of uPA at 2,000 IU/kg in this model. Almost no significant fibrinogen breakdown was observed either in vitro and in vivo.
 ...
PMID:A recombinant antibody-targeted plasminogen activator with high affinity for activated platelets increases thrombolytic potency in vitro and in vivo. 1068 Jun 44